Large-cell neuroendocrine tumors (NETs) are poorly differentiated malignancies of rare
incidence and aggressive nature. NETs mostly arise in the lung followed by the gastrointestinal
tract, although they are potentially ubiquitous throughout the body. Primary unknown NET
has a worse prognosis and shorter survival comparing with other NETs, with limited available
data in the literature concerning this subgroup. The authors report the case of large-cell
NET with supraclavicular lymph node presentation. Total excisional biopsy revealed an enlarged
adenopathy 18 × 15 × 10 mm, which was extensively infiltrated by a solid malignant
neoplasm composed of large cells with granular chromatin, nuclear pseudo-inclusions, high
mitotic index, and focal necrosis, with a Ki 67 index 25-30% and positive immunohistochemical
study for the expression of cytokeratin 8/18, chromogranin, synaptophysin, and thyroid
transcriptional factor-1 (TTF-1). There was no evidence of primary location apart from two
infracentimetric lung lesions that could not be accessed for biopsy and were negative at both
somatostatin receptor scintigraphy and positron emission tomography. The NET relapsed
with three mediastinal masses, so the patient was started on chemotherapy with carboplatin
and etoposide with initial total response. Early progression showed no response to further
chemotherapy regimens (temozolomide, oral etoposide); therefore, the patient was treated
with local radiotherapy. This patient has an atypical long survival (54 months) compared
to the literature data. In fact, there are few long-term survivors of large-cell NET and they
are all related to complete surgical resection.